CS
TCRT icon

Credit Suisse’s Alaunos Therapeutics TCRT Stock Holding History

Credit Suisse’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-1,000
Closed -$1.35M – 4353
2015
Q3 		$1.35M Buy
+1,000
New +$1.65M ﹤0.01% 2553

Other funds holding TCRT

MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Credit Suisse's TCRT Position: Q3 2022 in Review

Credit Suisse held its Alaunos Therapeutics (TCRT) position steady in Q3 2022 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #4281.

Credit Suisse first reported a position in TCRT in Q2 2013 and has held it in 36 quarters since. The position peaked at $3.99M in Q3 2015. 125 funds tracked by Wall St. Rank hold TCRT as of Q3 2022.

  • Credit Suisse held 0 shares of Alaunos Therapeutics worth $0 as of Q3 2022.
  • Credit Suisse left its Alaunos Therapeutics share count unchanged in Q3 2022.
  • Alaunos Therapeutics made up ﹤0.01% of Credit Suisse's portfolio in Q3 2022, its #4281 holding.
  • Credit Suisse first reported a position in Alaunos Therapeutics in Q2 2013 and has held it in 36 quarters since.
  • Credit Suisse's Alaunos Therapeutics position peaked at $3.99M in Q3 2015.
  • 125 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q3 2022.

Based on Credit Suisse's 13F filing for Q3 2022, filed 10 Nov 2022.